HomeDRREDDY • NSE
add
Dr Reddy's Laboratories Ltd
Nakaraang pagsara
₹1,208.65
Sakop ng araw
₹1,198.05 - ₹1,215.60
Sakop ng taon
₹1,074.00 - ₹1,421.49
Market cap
1.00T INR
Average na Volume
1.53M
P/E ratio
18.75
Dividend yield
0.67%
Primary exchange
NSE
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
(INR) | Set 2024info | Y/Y na pagbabago |
---|---|---|
Kita | 80.16B | 16.51% |
Gastos sa pagpapatakbo | 29.72B | 24.54% |
Net na kita | 12.55B | -15.18% |
Net profit margin | 15.66 | -27.20% |
Kita sa bawat share | 15.83 | -11.13% |
EBITDA | 22.02B | 8.53% |
Aktuwal na % ng binabayarang buwis | 30.01% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
(INR) | Set 2024info | Y/Y na pagbabago |
---|---|---|
Cash at mga panandaliang investment | 63.07B | -7.15% |
Kabuuang asset | 465.96B | 34.27% |
Kabuuang sagutin | 156.67B | 66.79% |
Kabuuang equity | 309.28B | — |
Natitirang share | 833.05M | — |
Presyo para makapag-book | 3.30 | — |
Return on assets | 10.24% | — |
Return on capital | 13.21% | — |
Cash Flow
Net change in cash
(INR) | Set 2024info | Y/Y na pagbabago |
---|---|---|
Net na kita | 12.55B | -15.18% |
Cash mula sa mga operasyon | 9.32B | -48.03% |
Cash mula sa pag-invest | -19.07B | -322.21% |
Cash mula sa financing | 16.15B | 329.53% |
Net change in cash | 6.37B | 1.03% |
Malayang cash flow | 3.92B | -72.47% |
Tungkol
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
CEO
Itinatag
1984
Headquarters
Website
Mga Empleyado
27,048